FMC director Luc Tack buys $14,078 in common stock

Luc Jules R Tack, a director and 10% owner of FMC Corp, recently bolstered his stake in the company by purchasing 2,514 shares of FMC's common stock. The transaction, executed on November 10, 2026, saw Tack invest $14,078 for the shares, which were acquired at $5.60 per share. As FMC's stock experienced a significant decline, trading at $5.06, or a staggering 62.76% drop year-to-date, the insider purchase garnered attention.

InvestingPro analysis revealed that the stock appeared undervalued, with a Fair Value of $7.01, hinting at potential upside. Notably, FMC pays a substantial dividend, currently yielding 6.32%. For those seeking further insights, an in-depth Pro Research Report on FMC, along with 11 exclusive tips, is accessible through InvestingPro's extensive collection of 1,400+ reports.

This insider move brought Tack's indirect beneficial ownership of FMC common stock to 31,111,680 shares, held through Tessenderlo Group NV, a company under Luc Tack's control. Tessenderlo Group NV also possesses the right to nominate a board member, as per an Investor Agreement dated September 23, 2026, making Tack an indirect director for Section 16 purposes.

Recent financial results painted a challenging picture for FMC, with adjusted earnings per share (EPS) at a negative $4.41 and revenue at $105.6 million for the third quarter. The company's woes stemmed from significant commercial charges and a strategic overhaul targeting inventory issues and bolstering business operations in North America.

Despite the weak earnings, FMC remained cautiously optimistic about a recovery in 2027, with preliminary EBITDA guidance ranging from $650 million to $730 million. However, full-year 2026 free cash flow guidance was adjusted to a negative range between $350 million and $150 million.

In related news, investment firm Jefferies initiated coverage on FMC with a Hold rating, citing pricing headwinds and establishing a price target of $6.00. The firm acknowledged that FMC's third-quarter results aligned with prior announcements, citing inventory and pricing adjustments as expected. Although the company faced obstacles such as reduced replenishment orders and patent protection loss for certain products, the longer-term strategic reset instilled optimism among investors.